Journal: International journal of cancer
This retrospective study evaluated the impact of renin-angiotensin-aldosterone system inhibitors (RAASi) on outcomes in 286 patients with advanced lung cancer treated with immune-checkpoint inhibitors (ICIs).
Key points include:
- 33% of the patients received RAASi concurrently.
- Patients on RAASi had significantly longer median overall survival (17.47 vs. 10.02 months).
- They also showed longer progression-free survival (8.31 vs. 3.84 months).
Multivariate analysis identified RAASi use as an independent predictor of improved overall survival, with a strong trend toward improved progression-free survival.
These findings suggest that RAASi may provide a synergistic benefit with ICIs in advanced lung cancer and support the need for prospective clinical trials to confirm this potential therapeutic synergy.